自噬相关基因在乳腺癌ET方案新辅助化疗疗效预测中的作用

目的：明确自噬相关基因在乳腺癌ET方案（表柔比星＋多西紫杉醇）新辅助化疗疗效预测中的作用。方法回顾性收集41例接受ET方案新辅助化疗患者化疗前的乳腺癌病理组织标本，分别以蛋白质印迹法（Westernblot）、实时荧光定量PCR及免疫组织化学检测各组织中自噬相关基因Atg3和Beclin1的表达情况，并通过统计学Fisher确切概率法，分析化疗前Atg3和Beclin1表达与化疗后疗效的关系。结果经Westernblot、实时荧光定量PCR及免疫组织化学检测发现41例化疗前乳腺癌组织标本中有24例Atg3与Beclin1高表达，其中化疗后有效者（完全缓解或部分缓解）23例（95．8％），无效者（疾病进展）1例；另17例乳腺癌组织Atg3与Beclin1化疗前无表达或低表达，其中化疗后有效者（完全缓解或部分缓解）3例（17．6％），无效者（疾病稳定或疾病进展）14例。化疗前Atg3与Beclin1高表达的患者化疗有效率明显高于无表达或低表达患者（P＜0．05）。结论 Atg3与Beclin1高表达可作为预测乳腺癌ET 方案新辅助化疗疗效的指标之一。

The role of autophagy-related genes in the evaluation of therapeutic effect of ET regimen neoadjuvant chemotherapy in breast cancer

Objective To identify the role of autophagy‐related genes in prediction of therapeutic effect of ET regimen neoadju‐vant chemotherapy in breast cancer .Methods Breast cancer tissues were retrospectively collected from 41 cases of breast cancer pa‐tients that treated by ET regimen neoadjuvant chemotherapy with different therapeutic effects .Expressions of Atg3 and Beclin1 ,and the autophagy‐related genes ,were detected by Western blot ,Real‐time PCR and immunohistochemistry in these tissues to observe their expressions before neoadjuvant chemotherapy .Statistical test was used to analyze the relationship between Atg3 ,Beclin1 ex‐pressions and therapeutic effects of ET regimen neoadjuvant chemotherapy .Results Western blot ,Real‐time PCR and immunohis‐tochemistry revealed that expressions of Atg3 and Beclin1 were up‐regulated in 24 breast cancer tissues before neoadjuvant chemo‐therapy ,including 23 cases of complete response(CR) or partial response (PR) (95 .8% ) and 1 case of progressive disease (PD) . Atg3 and Beclin1 were not expressed or lowly expressed in the other 17 cases ,including 3 cases of CR or PR (17 .6% ) and 14 cases of no change and PD .The effective rate of ET regimen neoadjuvant chemotherapy in breast cancer patients with over expression of Atg3 and Beclin1 was significantly higher than those with low expression or without expression of Atg3 and Beclin1 (P<0 .05) . Conclusion Over expression of Atg3 and Beclin1 could be new indicators for therapeutic effect of ET regimen neoadjuvant chemo‐therapy in breast cancer .